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ABSTRACT
Stroke is the third leading cause of death and a major debilitating disease in the United
States. Multiple factors, including genetic factors, contribute to the development of the
disease.

Genome-wide association studies (GWAS) have contributed to the

identification of genetic loci influencing risk for complex diseases, such as stroke.

In

2010, a GWAS of incident stroke was performed in four large prospective cohorts from
the USA and Europe and identified an association of two Single Nucleotide
Polymorphisms (SNPs) on chromosome 12p13 with a greater risk of ischemic stroke in
individuals of European and African-American ancestry.

These SNPs are located 11

Kb upstream of the nerve injury-induced gene 2, Ninjurin2 (NINJ2), suggesting that this
gene may be involved in stroke pathogenesis.

NINJ2 is a cell adhesion molecule

induced in the distal glial cells from a sciatic-nerve injury at 7-days after injury. In an
effort to ascribe a possible role of NINJ2 in stroke, we have assessed changes in the
level of gene and protein expression of NINJ2 following a time-course from a transiently
induced middle cerebral artery ischemic stroke in mice brains. We report an increase in
the gene expression of NINJ2 in the ischemic and peri-infarct (ipsilateral) cortical
tissues at 7 and 14-days after stroke. We also report an increase in the protein
expression of NINJ2 in the cortex of both the ipsilateral and contralateral cortical tissues
at the same time-points. We conclude that the expression of NINJ2 is regulated by an
ischemic stroke in the cortex and is consistent with NINJ2 being involved in the recovery
time-points of stroke.
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CHAPTER ONE
Literature Review

1

INTRODUCTION
Stroke is the third leading cause of death (Lloyd-Jones, D. et al., 2009) and a major
debilitating disease in the United States (Hankey, G. and Warlow, C., 1999).

It is

estimated that every 4 minutes someone dies from a stroke (Lloyd-Jones, D. et al.,
2009). This, along with an increase in the population (Thrift, A. et al., 2001), suggest
that stroke will continue being a significant financial burden for our economy. Costs
associated with stroke are expected to reach a peak of 1.52 trillion dollars by 2050
(Lloyd-Jones, D. et al., 2009).

In order to prevent more associated costs from stroke,

there is a need to identify the causative factors leading to the development of the
disease and address gaps in stroke research.
This thesis reviews the major risk factors for stroke, including genetic risk factors,
and the implementation of a Genome-wide Association Study (GWAS) as a tool to
identify genes for the disease.

It also delineates the major processes underlying the

pathophysiology of stroke and some of the conserved mechanisms of brain repair. This
thesis will then examine the patterns of expression of a GWAS-detected gene, nerve
injury induced gene-2 (NINJ2) in the brain of a mouse used to model a transient
ischemic stroke and discuss its potential contribution in the development of the disease.
The significance of this work lies in its attempt to follow-up on a hypothesis generated
by GWAS about the possible role of the NINJ2 gene in stroke. While GWAS studies
have begun to identify genetic loci associated with complex diseases, identification and
functional validation of the causal genes and understanding of their molecular
mechanisms of action in disease remains a daunting task. It is in light of this that
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determining the patterns of gene and protein expression of NINJ2 may provide an
insight of its potential contribution to the development of stroke.
BACKGROUND ON ISCHEMIC STROKE
There are two major types of stroke: ischemic and hemorrhagic. Ischemic stroke
is most frequent between the two and it is caused by an interruption in the oxygen
supply of brain cells (Bonita, R., 1992).

Stroke symptoms may involve intense and

localized headache, paralysis, speech impairment, and vision loss. The paralysis is on
the opposite side of the brain attack if the strike occurs in the left hemisphere of the
brain, the paralysis will be on the right side of the body. This is known as contralateral
hemiplegia (Good, D., 1990).
The Oxfordshire Classification System of Ischemic stroke subdivides the disease
into four subtypes based on the anatomic distribution of the brain infarcts and the
associated clinical manifestations (Bamford, J., 1991). The most widely used system of
classification in the clinics, however, is known as the Trial of Organization 10172 in
Acute Stroke Treatment (TOAST), and it uses the etiology of the disease to classify the
subtypes of ischemic stroke (Adams, H., et al., 1993). The TOAST classification system
consists of four major ischemic stroke subtype categories. First, cerebral infarctions,
also known as athero-thromboembolic stroke, occlude major arteries of the brain,
including the Middle Cerebral Artery (MCA), Posterior Cerebral Artery (PCA, and
Anterior Cerebral Artery (ACA). The main reason of this major subtype is via an arteryto-artery embolism (Siebler, M. et al., 1994; Fisher, C. and Ojemann, R., 1986).

The

second subtype is due to small-vessel infarcts that affect deep areas of the brain

3

(Lammie, G. et al., 1997; Fisher, C., 1979). The third subtype includes the cardioembolic strokes from other determined etiology such as clots that arise from arteries
other than in the brain. The fourth subtype of ischemic strokes involves those that are
“cryptogenic,” meaning their cause is mostly undetermined (Adams, H. et al., 1993).
Each of these subtypes of ischemia constitutes 20% of the total number of cases
(Siebler, M. et al., 1994; Lammie, G. et al., 1997, EAFT Study Group, 1993).

The

remaining 20% of all the cases are of unknown cause (Amarenco, P. et al., 1992).
The advantage of using the etiology for the classification of a complex disease, such
as stroke, is that it facilitates the selection of therapies that better manage the outcomes
of each subtype of the disease. TOAST has become very useful in studies that require
the implementation of standardized subtyping methods of ischemic stroke.

For

instance, TOAST is used by human stroke studies that aim to determine the genetic
contribution with criteria from clinical diagnostic techniques like MRI (Chukwudelunzu,
F. et al., 2001).

Thus, the accurate classification of variability in the stroke phenotype

depends on the consistent organization of the subtypes of the disease.
PATHOPHYSIOLOGY OF ISCHEMIC STROKE
Most of what is known about the pathophysiology of stroke has come from
studies performed on cellular excitoxicity (i.e. Kolko, M. et al., 1999), oxidative stress
(i.e. Hirsch, E., 1993), mitochondrial dysfunction (i.e. Cedarbaum, J., et al. 1986) and
cellular apoptosis (i.e. Heintz, N., 1993).

This section outlines some of the major

mechanisms underlying the neuropathology of ischemic stroke.

These include the

disruption of ion homeostasis, reduction of cerebral blood flow, failure of bio-energetics,
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disruption of the blood brain barrier, creation of an anaerobic micro-environment, and
edema.
Vessel occlusion leads to a reduction in the Cerebral Blood Flow (CBF), or hypoperfusion to the brain tissue and the generation of an ischemic core.

Hypo-perfusion

disrupts the delivery of substrates required in the production of adenosine 5'triphosphate (ATP); thus, quickly leading to a failure in energy generation in the
surrounding tissue (Martin, R. et al., 1994; Katsura, K. et al., 1994). ATP depletion
activates energy-dependent ion transport channels, including presynaptic voltagedependent Ca2+ channels (Turski, L. et al., 1998). The intracellular accumulation of
Ca2+ ions quickly leads to the depolarization of neurons and glial cells (Martin, R. et al.,
1994), followed by the release of excitatory amino acids into the extracellular space
(Katsura, K. et al., 1994). Excitoxicity, along with the impediment in the presynaptic
reuptake of excitatory amino acids, such as glutamate, signals for the release of
reactive oxygen species (ROS) into the postsynaptic cells (McMahon and Nicholls et al.,
1990).

Membrane permeation by ROS contributes to the disruption of the blood-brain

barrier (Dugan, L. et al., 1994). The accumulation of ROS leads to the establishment of
an anaerobic environment where glycolysis and lactate production predominate (Nicoli,
F. et al., 2003; Brouns, R. et al., 2008). Abnormal anaerobic metabolism in stroke may
cause an intracortical infarction in deeper regions of the brain (Brouns R et al., 2008;
Uyttenboogaart, M. et al., 2007). This is prevalent especially after a middle cerebral
occlusion (Schneweis, S. et al., 2001). These events also lead to the recruitment of
activated macrophages to vascular endothelial cells and the subsequent activation of
post-inflammatory mechanisms (Zeller, J. et al., 2005; Chong, Z. et al., 2001).

The
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end result of all of these degenerative processes is micro-vascular injury at the acute
phase of a cerebral ischemia (Mohammadi, M., et al. 2011).
Furthermore, the accumulation of injured endothelial cells may induce
extravasation of extracellular fluid; thereby causing cytotoxic edema (Shaw, C., et al.
1959; Simard, J. et al., 2010).

Cytotoxic edema is primarily due to ATP depletion and

the subsequent opening of nonselective cation channels (NC Ca-ATP) (Simard, J. et al.,
2010).

A large cerebral edema results in the elevation of the intracranial pressure, a

shift in the brain tissue, and herniation in the brain tissue near the infarct core (Huttner,
H., et al. 2009). The latter is characteristic of a malignant MCA infarction since 80% of
patients with brain herniation die (Hacke, W. et al., 1996; Berroushot, J., 1998).
Particularly relevant in the prediction of malignancy is an early (within 6 hours of
symptoms) detection of edema with perfusion CT and diffusion-weighted magnetic
resonance imaging (Thomalla, G. et al., 2003; Thomalla, G. et al., 2010). The ischemic
cascades of events are quite traumatic for brain cells, especially for neuronal cell bodies
in the grey matter (Turski, L. et al., 1998). The micro-vessel architecture of the brain is
such that a severe impairment of blood flow in one major vessel rapidly translates into
the irreversible failure of blood supply in surrounding neurons (Turski, L. et al., 1998;
Ransom, R. et al., 1990). Moreover, these studies have led to the development of
acute phase therapies. However, most of these therapies have failed at the bedside
(Cheng, Y., et al., 2004), suggesting a change in the focus of investigation towards an
elucidation of compensatory pathways of recovery from a stroke.
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RECOVERY OF STROKE
Some phenomena of recovery following a traumatic brain injury have also been
shown to contribute to brain repair after a stroke.

An example is the co-induction of

elements of angiogenic plasticity after brain trauma (Navaratna, D. et al., 2009).

It is

suggested that enhancement of angiogenic repair and neural plasticity contributes to
neural repair and compensation of cerebral blood flow in the stroke penumbra (Thored,
P. et al, 2007; Ohab, J. et al, 2006; Taguchi, A. et al, 2004). In fact, some restorative
strategies aimed at protecting glial and endothelial function have been shown to induce
CBF in the post-ischemic brain tissue (Zhang, Z. et al., 2009).
The “penumbra” consists of salvageable tissue in the brain surrounding the necrotic
tissue from the stroke (Wise, R. et al., 1982). The penumbra is first detected minutes
after the onset of stroke, but it then becomes progressively worse as time passes by
(Kaplan, B. et al., 1991). The most adequate time for the reestablishment of CBF in the
penumbra is within the first 2 to 5 hours after the onset of stroke (Jones, T. et al., 1981;
Kaplan, B. et al., 1991).

Therefore, it is crucial that for the design of a cellular

treatment for stroke, not only should we explore the fundamentals of cell death
processes but also determine the activation of intrinsic mechanisms underlying tissue
repair in the stroke penumbra (Lo, H. et al., 2003).
RISK FACTORS FOR STROKE
It is of interest to determine the key factors that predispose certain people to the
disease. Determining the cause of these factors stroke (Khaw, K., 1996) and treating
them at an early stage (World Health Report, 1999; WHO Monica Project, 1988) is
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expected to significantly reduce the incidence of stroke.

One major causative risk

factor of stroke is an increase in the levels of diastolic blood pressure (DBP). In a
landmark study by McMahon et al. (1990), the direct contribution of high blood pressure
to an increasing risk for stroke was established.

This study followed up on a

Framingham study that first linked hypertension with an increase in the incidence of
ischemic stroke (Kannel, W., et al. 1970).

The McMahon prospective cohort study

demonstrates a cumulative risk of incidence of stroke in patients with high levels of
DBP.

It has been reported that treatment of vascular risk factors in hypertensive

patient groups at high risk of developing a stroke confers a proportional reduction in the
incidence of stroke (Wolf, P. et al., 1991). In general, a modest reduction in DBP levels
significantly reduces stroke incidence, especially in the aging population (McMahon et
al. 1990). These observations would forever change an erroneous concept that stated
that the reduction in CBF precipitates ischemic stroke in the elderly suffering from low
blood pressure (Wolf, P. et al., 2000).

Furthermore, these seminal studies served as

the foundation for clinical trials using at-risk patient populations, including the
Perindopril Protection against Recurrent Stroke Study (PROGRESS Collaborative
Group, 2001). In the PROGRESS study, it was suggested that a modest reduction in
the DBP level from population-wide and at-risk population groups confer benefits to the
reduction of neurological deficits of stroke, such as dementia (Ott, A. et al., 1998; Liao
DP et al., 1996; Skoog, I., 1993).
Other causative risk factors of stroke, apart from hypertension (Kannel, W., et al.
1970; MacMahon, S., et al., 1990), include a history of a previous transient ischemic
attack (Bamford, J. et al., 1991) and/or other cardiovascular diseases such as diabetes
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mellitus (WHO Expert Committee on Diabetes Mellitus) and atrial fibrillation (Hart et al.,
1999). There are also other risk factors of stroke that confer an increase in the overall
risk of stroke (McMahon, H. et al., 1990). For instance, large BMI due to an unhealthy
lifestyle and lack of exercise (Hu et al., 2005 and 2007), smoking (Mancia, G., et al.
1990), and high carbohydrate diet (Chiba, T. et al., 2009) may complicate the risk of
stroke.
GENETIC RISK IN STROKE
Stroke is a multifactorial and complex disease.

Nevertheless, there is also

substantial data that suggest genetic component underlying stroke susceptibility (Turski
L. et al., 1998). In fact, a Framingham study in the 1970s first reported a significant risk
of developing the disease in people with a parental history of stroke, suggesting a
familial contribution to the risk of stroke (Kannel, W.B. et al., 1970). Later in the 1990s,
Kiely et al. followed up on this study using data consisting of familial aggregation of
stroke. The Kiely et al. study reported a direct association between parental history of
stroke and increased risk of stroke (Kiely, D. et al. 1993); an observation that would
then be confirmed in the Family Heart Study (Liao, D. et al., 1997).
A twin study performed by Brass et al. (Brass, L. et al. 1992), and later confirmed in
a study by Bak et al. (Bak, S. et al., 2002), also provides strong evidences for genetic
risk in stroke. The primary role of twin studies is to distinguish between shared family
effects without a genetic contribution from those that do arise from genetic effects.

A

twin study usually involves comparing monozygotic (MZ) twin pairs with dizygotic (DZ)
twins. MZ twins share all of their genes while DZ twins only share half of their genes.
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Twin studies use the concordance rate to determine the genetic contribution to the
development of a disease (McGue, M., 1992).

A study showing MZ and DZ twins

having 100% and 50% concordance rates, respectively, constitute a complete genetic
determination for the disease (MacGregor, A. et al. 2000). Results from the Brass et al.
study report a 17.7% for the concordance rate in MZ and 3.6% concordance rate in DZ
twins, suggesting a significant genetic predisposition to stroke (Brass, L. et al., 1992).
Furthermore, there is a central assumption in twin studies that calls for an equal
environmental exposure by both MZ and DZ twins (Kendler, K., et al. 1993; Guo, S.
2001). Yet, this assumption may not always be true. If the concordance rates for both
MZ and DZ twins are similar to each other, then an environmental rather than a genetic
effect is to be suggested (Risch, N. 2001). For instance, a later study by Brass reports
there is an additive environmental effect as the patients increase in age (Brass, L.,
2000), as it is to be predicted from the similarity in the concordance rates between the
MZ and DZ twins from the first study.
However, much of what has been learned about the genetic of stroke has come
from studies on single gene Mendelian disorders associated with stroke. One example
is

Cerebral

Autosomal

Dominant

arteriopathy

with

Leukoencephalopathy (CADASIL) (Joutel, A. et al., 1997).

Subcortical

Infarcts

and

CADASIL is characterized

by a progressive disruption of the vascular endothelium and thrombosis, both of which
manifest among subpopulations of stroke (Ruchoux, M. et al., 1998). And yet, there is a
limit in determining a genetic risk in the general population from single gene disorders.
People with CADASIL, for instance, do not respond to the regular treatment plan with
tPA used for the other subtypes of stroke (Viitanen, M. et al 2000). Consequently, a
10

treatment originally designed for the single-gene disorder may not necessarily work for
the treatment of other subtypes of stroke.

Thus, it can be suggested that the genetic

contribution of a single-gene disease is not sufficient for the development of all other
types of stroke. Hence, it is necessary to implement a genome-wide approach to find
genes that may be linked to stroke.
GENOMEWIDE ASSOCIATION STUDY (GWAS)
Novel methods from genetic epidemiology, such as genome-wide association
studies (GWAS), have contributed to the genomic analysis of complex diseases (Hanis,
C., et al. 1996; Collins, F. et al. 1997).

GWAS studies are commonly designed using

either retrospective case-controls or prospectively multi-national cohorts.

In a case-

control study, samples are taken from diseased subjects at medical care centers,
together with samples from age and gender matched control subjects.

Cohort studies

consist in sampling all the members of a population, regardless of age or gender. A
GWAS analyzes millions of SNPs from multi-national cohorts with large sample sizes of
diseased and healthy people enrolling into the study. The study consists of determining
the frequency of SNPs in the healthy population and comparing it with the frequency in
the diseased population.

A p-value is assigned to every SNP and a significant

difference from the norm is reached when the p-value is lower than a pre-specified
threshold (Manolio, T., et al. 2010).
Thus, a GWAS study provides the association of SNPs with the disease as well
as genes in close proximity with the associated SNP (Tu, I. and Whittemore, A., 1999).
These genes, however, are not necessarily the cause of the disease since a GWAS
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study is based on the principle of linkage disequilibrium (LD) (Manolio, T., et al. 2010).
The underlying assumption of LD is that the physical distance between the genetic
marker and the disease gene is small enough to demonstrate an allelic association at
the population level (Weiss, K. 2002).

Most associations usually represent a

susceptible locus that increases the chance of developing the disease (Greenberg, D.
1993). Furthermore, the GWAS approach has had success in identifying associations
of genetic markers with complex conditions such as diabetes, cardiovascular
abnormalities and Parkinson disease (Johnson, A. et al. 2009).

To date, there has not

been many GWAS studies published on the genetics of stroke. In fact, the first GWAS
study ever published in ischemic stroke is from Matarin et al. in 2007. The case-control
study from Matarin et al. did not reveal any locus that contributes to a higher risk in the
development of ischemic stroke (Matarin M. et al., 2007).

The major limiting factor of

this study is its small sample size, followed by the use of a control design with large
survival and selection biases.
In 2010, a GWAS study is performed with four large prospective cohorts from
the USA and Europe. These cohorts are all part of an international consortium known
as the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE)
(Psaty, B. et al., 2009). Overall, the CHARGE consortium contributed with a sample
size of 19,602 participants of European ancestry followed prospectively over an average
period of 11 years (Ikram, M. et al., 2010). A total of 1544 incident strokes developed
over the follow-up period. 1164 of these are ischemic strokes. In this study, stroke is
defined with the WHO definition as stated above (WHO, 1999). The types of stroke
studied are ischemic, hemorrhagic, or “unknown,” all assessed by clinical and imaging
12

criteria.

Ischemic stroke is further subdivided into the atherothrombotic and

cardioembolic subtypes (Ikram, M. et al., 2010). The GWAS identified an association in
two Single Nucleotide Polymorphisms (SNPs) on chromosome 12p13 with a greater risk
of ischemic stroke in individuals of European and African-American ancestry.

These

SNPs are located 11 Kb upstream of the NINJ2, suggesting that this gene may be
influencing stroke risk.
THESIS OVERVIEW
This thesis reports changes in mRNA and protein levels of NINJ2 following a transient
focal cortical ischemic stroke in mice using a middle cerebral artery occlusion (MCAo)
model. This is done in order to determine whether NINJ2 is involved in ischemic stroke.
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CHAPTER TWO
EXPERIMENTAL METHODS
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MIDDLE CEREBRAL ARTERY OCCLUSION (MCAo)
Background
The implementation of a well-designed biological model in mice is crucial for a
quantitative study of the differential gene expression in the diseased state. Animal
models for neurodegenerative diseases have revealed some of the mechanisms
underlying risk factors of disease (Bacigaluppi M., et al. 2010).

Three of the major

caveats of animal models of stroke are high mortality rate and low reproducibility in
determining disease mechanisms (Garcia-Bonilla L. et al., 2011).

We perform a

transient Middle Cerebral Artery occlusion (MCAo) in 9-10 weeks old male wild-type
C57BL/6 mice. The stroke is focal to the cortex and reproducible between animals. The
advantage of using this animal model is that it reduces the death rate of mice and
increases reproducibility of the biochemical studies from brain tissues. In the case of
the transient stroke mouse model, replicating the same degree of necrosis across all
brain tissues depends on the time in which the mice are subjected to the stroke as well
as surgeon’s skills in performing the surgery. The tandem and reversible induction of
ischemic stroke also permits for the visualization of the penumbra in a mouse’s brain.
Extracting tissue from the penumbra is required for the detection of changes in
expression of genes that may be involved in the recovery phases of a stroke.
Transient MCAo Induction – Mr. Roger Strong, in collaboration with Dr. Jaroslaw
Arnowski, induced a focal ischemia following a left middle cerebral artery (MCA), and left
common carotid artery (CCA) transient occlusion scheme as summarized below
(Waxham, M. et al., 1996).

A day before the surgery, an overnight starving order is
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placed for a maximum of five mice per day. On the day of the surgery, mice are taken
to the surgery room where they are weighed and anesthetized with chloral hydrate (350
mg/kg). The temporal side of the mouse’s head as well as its neck is barbed while the
mouse remained unconscious. The surgical procedure started by making a small burr
hole with a surgical electrical hand-drill over the MCA without touching any of the
cerebral arteries and causing intracranial bleeding.

Once the MCA is exposed under

the magnification of an inverted microscope, a 3 mm stainless steel wire is inserted
“underneath the MCA rostral to the rhinal fissure, proximal to the major bifurcation of the
MCA, and distal to the lenticulostriate arteries” (Waxham, M. et al., 1996). The artery is
then pushed towards the cortex and then rotated counterclockwise. Immediately after,
the common carotid artery is occluded using autramatic Heifetz aneurysm clips in order
to facilitate the transient induction of a cortical stroke.
Measurement of Cerebral Blood Flow (CBF) – CBF is measured prior to and
immediately after placing the subcortical wire in the mouse brain using a laser Doppler
flowmeter.

90 minutes after the surgery, the CBF is reperfused into the brain by

removing the aneurysm clips from the CCA, rotating the wire counterclockwise on the
MCA, and removing the wire from the brain. CBF is then measured again.
Body Heat Regulation – The mouse is placed on top of a warm plate throughout the
duration of the procedure in order to maintain the body temperature at the physiological
level of 37oC +/- 0.5oC. The feed-forward temperature controller, coupled to a heating
lamp and a warm plate are used to maintain a stable core body temperature (Waxham,
M. et al., 1996).
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Mouse Care – Mice arrived from Jackson Laboratory and left to acclimatize at room
environment of the Animal Care Facility over a period of 3 days. In the meantime, mice
are fed with standard mouse diet and housed in standard mouse cages on a 12 h
inverted light/dark cycle. All experimental procedures are approved by the Institutional
Animal Care Committee of University of Texas Health Science Center at Houston at the
Medical School.
HARVESTING OF MOUSE BRAIN TISSUES
Experimental Timeline for Brain Extraction – The time points of brain extraction are 0
hours, 3 hours, 24 hours, 7 days, and 14 days after stroke. 3 mice are randomly taken
from each group in the timeline of experiments.

A mouse is removed from the cage

and anesthetized. The mouse’s heart is then perfused with ice cold PBS following the
approved animal protocol for perfusion.

Tissue Dissection– Mice brains are dissected

in such a way that the cortex is preserved with the least amount of time spent at room
temperature (RT). The time allowed for brain tissue to be at room temperature is of less
than 30 seconds in order to preserve the functional stability of proteins. The brain is
placed on a brain dissecting mold and sterile blades are used to cut 2-3 mm of the brain
tissues. The isolated brain is quickly washed with ice cold 1X PBS pH 7.4, carefully
dried with a damped paper towel, placed on a brain mold, cut into the corresponding
sections, and dissected on a petri dish with cold PBS. Figure 2.1 shows an example of
the tissue sections stained with TTC.
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Figure 2.1 TTC stained brain tissue sections after a stroke. Dissected 200um sections of a
mouse brain 24 hours after a transient Ischemic stroke of 90 minutes. These sections are
stained with TTC for mitochondria. The red line in this figure outlines the necrotic cortical tissue,
namely the ipsilateral tissue, and the penumbra. The blue shadow represents the contralateral
tissue. Both the ipsilateral and the contralateral tissues are cut in the same size.

Cortex Extraction – A surgical knife is used to dissect the brain into two hemispheres,
keeping the injured hemisphere on one side. The cortex is then removed with a blunted
knife by making an incision through the corpus callosum.

The cortex consists of the

outermost brain tissue. A small piece from the cortical tissues of each hemisphere is
harvested for the biochemical studies, as shown by the demarcations in figure 2.1.
Sample identification and preservation – Once the tissue dissection is made, the cortical
and striatal tissues are preserved in eppendorff tubes labeled as followed: 1 for injured
cortex, 2 for contralateral cortex, 3 for injured striatum, and 4 for contralateral striatum.
Once all the brains are extracted and placed at -80oC for at least 24 hours, they are
then ready for homogenization.
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GENE EXPRESSION PROFILING OF NINJ2 AFTER A STROKE
RNA Isolation – Total RNA is isolated from each brain tissue using the Trizol method.
Basically, 1 ml of Trizol reagent (Gibco-BRL) is added onto glass test tubes to
homogenize the brain tissues. The cortical tissues are added one by one from the 80oC stock onto tubes containing the Trizol reagent. The plastic pistol is moved up and
down the test tube 6 times for 10 seconds each. The tissue is placed on ice for 40
minutes until a stringy-like material appeared.

1/10 volume of chloroform (99%

stabilized with chylenes) is added to it. Samples are vortexed for 15 seconds vigorously
and left on ice for 5 minutes. Samples are then spun down in a microfuge at 13.2 rpm
for 20 minutes at 4oC.

The top layer (clear) is carefully transferred into a new RNAse

free eppendorf tube and 1/10 volume of 3M sodium acetate is added to it, followed by
the same volume (55µl) of Isopropanol.

The solutions are gently inverted to mix.

Samples are spun in a microfuge at 13.2 rpm for 30 minutes at 4oC. RNA is seen as a
nice white pellet at the bottom.

The pellet is then washed with 70% cold ethanol

(made by diluting into DEPC-treated water).

Diluted samples are centrifuged in

microfuge at 13.2 rpm for 5 minutes at 4oC. Supernatant are removed and the samples
are left to dry.

The pellet containing the RNA is air dried for 10 minutes. Pellet is

dissolved in 70 µl of DEPC-treated water and samples are heated for 10 minutes at
60oC to help dissolve RNA.

RNA concentration is measured at 260 µm using a

nanodrop (Aronowski Lab Protocol).

Once the RNA is extracted from the tissue

homogenate, the cDNA is synthesized in order to determine changes in gene
expression.
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RNA-cDNA reaction – Reverse transcription of the RNA samples into the cDNA are
prepared in the following manner. The High Capacity RNA-to-cDNA Kit (Part #
4387406) components are allowed to thaw on ice. The lab bench areas as well as the
gloves are cleaned thoroughly with 70% Ethanol and RNAse ZAP in order to remove
any potential contaminant on the surface. An RNA aliquot is removed from each brain
sample placed in the -80oC freezer and placed on ice. The RNA aliquots are prepared
so that the final concentration yields 0.25 µg/µl per sample.

The RNA-to-cDNA

reaction involves using 1ug of RNA. 4 µl of the RNA aliquot is filled to a total of 10 µl
volume with 6µl of nuclease free ddH2O. The diluted RNA solutions (1ug total) are
heated to 70oC for 10 minutes in order to destroy secondary RNA structures. The 2X RT
Master Mix is also prepared on ice using the components from the RT Kit and following
the instructions indicated in the appendix. 10ul of the 2X RT Master Mix is added into
the heated RNA solutions (total volume of 20ul). The tubes are sealed and briefly
centrifuged to spin down contents and eliminate bubbles. It is assumed that for every
microliter of solution in the RNA-cDNA reaction tube, 1000 ng or 1 µg of cDNA
molecules are produced. The complementary DNA (cDNA) molecules produced in the
first step of the reaction serves as the template for the qPCR reaction. The qPCR
reaction is the second step after the synthesis of the cDNA.

DNA is more stable than

RNA and the relative number of cDNA molecules produced in the first step of the
reaction by the RNA polymerase is directly proportional with the number of RNA
molecules present in the sample.
Quantitative Polymerase Chain Reaction (QPCR) – We implement qPCR to quantify
changes in gene expression following a stroke in mice brains. The basis for qPCR
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consists in the use of Taqman chemistry, consisting of a fluorescent probe attached to a
chemically synthesized DNA primer.

The taqman probe contains two molecules: a

fluorophore and a quencher. As the DNA polymerase extends forward in the DNA, the
fluorophore is separated from the quencher and it releases a fluorescent signal that is
read by the machine. The primer is complementary to a conserved DNA sequence in
the gene of interest onto which the DNA polymerase binds to and mediates cloning of
the DNA. Commercially available primers are used for NINJ2, RPOL2, and INOS2 with
sequences evaluated for transcript specificity, genomic DNA specificity, and other
functional considerations as stated in the appendix.
Plate Design – A flexible template in Microsoft Excel is created for the analysis of the
raw data. An example of this template is shown in the appendix (A1). Basically, each
plate carries both the target and endogenous gene probes, along with the cDNA
samples from tissues of the control and experimental brains. The target gene is added
to the top 4 rows, followed by the endogenous genes on the bottom 4 rows. The
experiments are designed such that the whole time-line of expression would fit into two
plates named as Injury and Recovery plates. Both plates shared a group of samples
consisting of cDNA from mice sacked at the 3rd day after the stroke. This serves as an
internal control to lower the inter-assay variability between experimental runs.
Standard Curve – A standard curve is generated for every qPCR plate using cDNA from
the cortical tissue of a healthy mouse brain used as a naïve sample in the
experimentations. There are usually two to three serial dilution points in each standard
curve.

The reason for incorporating the standard curve is to calculate the qPCR

amplification efficiency and also keep a control on the quality of qPCR reagents.
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Independent sets of standard curves are also prepared for each probe using a larger
number of dilution points.
GENE EXPRESSION ANALYSIS
Introduction to Methods of Analysis – There are two main methods of presenting the
gene expression data from quantitative Polymerase Chain Reaction signals (qPCR):
absolute and relative quantification.

In the absolute quantification method, the copy

number of the gene is calculated using a standard curve. The standard curve
transforms the qPCR signal to an exact copy number (Chen C et al., 2005). Absolute
expression is necessary when presenting a precise quantity of amplicon.

The

disadvantage of absolute quantification is its strict dependence on standard curves for
data analysis.

In this section of the chapter, the method followed for the relative

quantification of changes in NINJ2 gene expression in brain tissues is explained. The
selection process of the endogenous gene and the basic mathematical assumptions for
all these calculations, including the calculation of the qPCR amplification efficiency, are
also explained.
Amplification Data – The qPCR reaction generates a log-linear plot of the fluorescence
signal versus the cycle number. The endpoint of the qPCR analysis is defined by a
threshold cycle (CT) value and it represents the exponential phase of the PCR
amplification of the gene.

The CT value is inversely proportional to the amount of

amplicon in the reaction. Given the exponential nature of the CT terms, the use of raw
CT values is avoided in the tests of statistics as well as for Relative Quantification (RQ)
calculations (Livak K. and Schmittgen, T., 2001).
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Comparative Ct method for Data Analysis – The comparative Ct method, also known as
the 2-•



T

method, is also implemented for the conversion of the CT values into

normalized relative quantities. This method is followed since it permits the analysis of
low input RNA from cortical tissues. This method is derived from a mathematical model
developed by Livak and Schmittgen (Livak K. and Schmittgen, T., 2001). Results from
this method yield the fold induction in NINJ2, normalized to RPOL2 and relative to the
average expression of the RQ values of all three mice at time zero.

The calculations

are performed with the RQ values of three mice per time-point repeated in three
experimental runs. First, the mean of the CT values corresponding to the technical
replicates of each sample is calculated. Then, the mean CT at time point zero for the
target and endogenous genes are calculated. Then, the CT value of the target gene of
each technical replicate is subtracted minus the CT value of the endogenous gene of
the corresponding sample. The mean CT value at time 0 of the target gene is then
subtracted from the mean CT at time 0 of the endogenous gene. The ddCT value is
computed for each technical replicate by subtracting the two values. The 2-ddCT is
computed from 2 to the negative power of the resultant value.

Calculations are

performed for each qPCR experimental run.
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Figure 2.2 Use of Comparative CT method to determine the Mean Fold Change in
Gene Expression.

Implementation of the 2-䌆 T method for the Endogenous Gene selection – The effect of
experimental treatment (MCAo stroke) on the expression of the endogenous reference
is studied using the 2-䌆 method, a derivative of the 2-•



T

method.

The 2-䌆 method

converts the CT values from the exponential to the linear form, thus permitting the
validation of the candidate internal control gene (RPOL2).

Validation consists in

determining the effect of the experimental treatment on the expression of RPOL2 (Livak
K. and Schmittgen, T., 2001). The same concentrations of input RNA are used to
generate cDNA for all the reactions, as shown in the appendix.
Amplification Efficiency – The qPCR amplification efficiencies for the target (NINJ2) and
control (RPOL2) genes are calculated according to equation 1. The underlying
assumption of the efficiency calculation is that it is “assay dependent and sample
independent” (Hellemans J. et al., 2007).

Thus, the amplification efficiencies are

calculated using aliquots of cDNA isolated from cortical tissues of naïve mice.

The

amplification efficiency is determined with a linear regression of a serial dilution series
from known quantities of cDNA concentrations.
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Eq. 1:
The efficiency values are converted to percent efficiencies using an equation (Eq. 1a)
derived from Eq. 1.

Eq. 1a:
This experimental design permits the analysis of the amplification efficiencies for both
target and endogenous probe assays.
determined by

Equal qPCR amplification efficiencies are
(Perkin Elmer

and Pfaffl M. 2001). This is the initial presumption for the delta-delta Ct method to hold
true (Ruijter J.M. et al., 2009). It can be suggested that, under this condition, both
target and reference probes are selective for their complementary sequence in the gene
of interest. It also suggests there are no inhibitors in the reaction from the RNA isolation
process (Perkin Elmer).
Statistics – A total of 3 replicates of the experiments are performed with 3 animals per
experiment, representing the three time-points following stroke. All analyses are
conducted using SAS9.2 statistical software. Data are analyzed using a mixed model to
account for the correlation between the replicate experiments. Gene expression levels
are modeled as a function of time groups and experiment groups with repeated
measures on the latter group. Covariance structure for the repeated measurements is
modeled as unstructured. Pairwise differences in means between time points are tested
using a t-test. P values are corrected for multiple comparisons using a Tukey-Kramer
procedure.
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NINJ2 PROTEIN EXPRESSION AFTER A STROKE
Lysis Buffer Preparation – The purpose of this section is to detect NINJ2 protein in
tissues of brain from mice with a commercially available antibody. The commercially
available antibodies reported various molecular size for NINJ2, thus a gradient gel is
used to determine changes in signal levels across a whole range of molecular sizes.
The mouse brain and lung tissues are used to determine changes in the level of NINJ2
proteins following a stroke. The lung tissue is used since it is where NINJ2 is highly
expressed. The highest expression of the NINJ2 gene is in the mouse lung (Milbrandt et
al., 2000). For this, a lysis buffer is needed to prepare the tissues for protein analysis.
The lysis buffer used is the regular RIPA (pH 7.0) buffer stated on appendix B. This
RIPA buffer uses a mild detergent that disrupts the cellular membranes in the tissue and
preserves proteins in micelles. It also provides the necessary reagents that resembles
the physiological state of the cell and reduces the mechanical stress to the cellular
contents caused by the homogenization process. Prior to homogenization, 1 µl each of
the Protease inhibitor and Phosphatase inhibitor (1X) are added into the RIPA buffer.
This step disrupts the enzymatic action of the cellular proteases and phosphatases
released into the solution.
Tissue homogenization – The tissue samples in the RIPA buffer are lysed about a
minute in the following manner. The tissues are given 6-8 strokes in a glass tube using
a Teflon homogenizer, preventing foaming on the top. The Teflon homogenizer is used
instead of the douncer homogenizer in order to minimize protein disruption.

The
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homogenates are separated into multiple eppendorff tubes while kept on ice. In order to
prepare aliquots of the supernatant for analysis, some of the initial aliquots are
centrifuged at max speed (~14,000 rpm) for 10 minutes. The supernatants are stored in
the form of small aliquots and the whole homogenates are also saved for protein
sampling. 10 µl of each of the supernatant aliquots are saved for protein quantification.
Prior to removing samples from each aliquot, the aliquots are carefully shaken using a
vortex in a speedy manner so as to prevent protein degradation. Brain and lung lysates
are not thawed and frozen more than 2 times in order to prevent loss in the degree of
structure preservation.
SDS-PAGE – The tissue samples are treated with 1X Loading Buffer (1:1) at RT before
running them in the gel. The loading buffer is prepared as a 4X stock and diluted to a
1X running solution as shown in the appendix. 15 µl of each sample, containing 80 µg
of protein, are diluted in a total volume of 20 ul with RIPA buffer. To make 20 µl of the
final solution, 6.6 µl of the 4X sample buffer stock is added on the sample, diluting it into
a final concentration of 1X. Once the samples are mixed with the loading buffer, these
are then processed for the protein gels.
Although the heating conditions varied, an optimized heating temperature is provided to
separate the NINJ2 protein from the rest of the proteins in the sample pool.

This

consisted in heating the samples at 60oC for 20 minutes during the electrophoretic run.
The mild heat and long-time process of sample preparation prevents unnecessary
protein aggregation caused by inducing hydrophobic proteins to conglomerate in boiling
conditions. The membrane domain of NINJ2 consists mostly of hydrophobic residues,
making it easy to aggregate at near-boiling temperatures. The 12% gels are casted
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using the protocol from Aronowski Lab as shown in the appendix. The 12% gel is used
to separate the mid-range molecular size proteins (12-50Kd). The premade Invitrogen
gradient gel is also used to confirm the results.

The procedure for running an

electrophoretic gel is summarized in the appendix.
Protein transfer – The procedure for the transfer of negatively charged proteins onto the
positive charged pvdf membrane is explained in the appendix. The protein transfer
differs from the norm in that it has to be done overnight at 25Volts and at 4oC.
Antibody Incubation –The PVDF membrane is first blocked with a blocking buffer
consisting of 0.5 g of powder milk in 10 ml of TBSt. This is done for 1 hour with gentle
shaking. The membrane is then rinsed with wash buffer before antibody incubation.
The antibodies used for the selection of the NINJ2 antigens in the tissue homogenate
(immunological incubation) have rabbit-derived IgG heavy chains and light chains with
motifs specific against mouse sequence. This antibody is acquired from Protein Tech
Inc.

This antibody is selected after having failed with multiple other antibodies that

gave a significant amount of background and non-selective identification of proteins in
the sample. The starting dilution of the P. Tech antibody is 1:200 and the final dilution
factor is 1:1000; yet the optimal dilution factor is that of 1:500. All of these dilutions are
done in the blocking buffer. The antibody incubation and film developing procedures are
shown in the appendix.
Selectivity of Antibody – The purpose of stripping the membrane is to confirm the
immunoreactivity of the Antibody. This is done by incubating the same membrane with
different dilutions of the antibody and stripping the antibody with the stripping solution as

28

shown in the appendix.

The same membrane is incubated with another antibody,

including the antibody provided by Milbrandt. This allows one to cross-check the results
seen at the level of protein’s molecular size reported in the literature. Peptide
competition assay – The purpose of this section is to use a peptide that is specific
against the protein of interest and, thus, block the binding of the primary antibody. The
peptide designed by Santa Cruz (sc-79653) maps the membrane domain of the protein.
The Protein Tech Company antibody is used for the reaction. The peptide competition
experiment is performed using a 200X molar ratio of peptide to antibody in order to
compete for the specific binding site in the antibody. The peptide sequences are
designed to be the same as the membrane domain of the mouse NINJ2 protein. The
peptide and antibody solutions are mixed in the blocking buffer solution at 4oC
overnight before using them to incubate the membrane containing the protein lysate
from the brain, lung, and NINJ2 transfected 293+T cells samples (Santa Cruz).
Overnight incubation is done in order to expose the antigenic site of the antibody longer
with the NINJ2 in solution. Results for the brain, lung and 293+T cells are shown in
figure 3.8.

A negative control is also run using water instead of peptides for both

experiments.

200 fold of molar excess of NINJ2 peptide is prepared in the same

solution. 4 ug of the peptide (0.2 ug/ul stock) and 0.2067 ug of primary Antibody (0.2066
ug/ul stock) are used for the preparation of the 200X peptide to antibody solution. The
blocking buffer (5% milk and 1% tween 20) is used as the diluent for the solution.
control sample is prepared using water instead of the antibody.

A

A membrane strip

containing the protein is incubated with the peptide/antibody solution overnight at 4oC.
A control membrane strip from the same protein is also incubated with the peptide/water
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solution overnight at 4oC. A secondary antibody attached to horseradish peroxidase is
used to develop the membrane with a chromogenic substrate.
Immunoprecipitation using Protein G Magna Beads –The purpose of using the magna
beads covalently linked to Protein G is to separate the protein of interest from the pool
of 1 ug of proteins in the supernatant of a brain tissue homogenate. The beads are
composed of silanized iron oxide, so they are surrounded by an external magnetic field
that is also super paramagnetic, with no magnetic memory (Thermo Scientific 21348).
This means that when a magnet is used, along with other non-disruptive chemicals, the
protein of interest (antigen) will become purified from the tissue culture. First, the 1:500
of the glycerol-based Protein Tech anti-NINJ2 antibody is mixed with 1gram of tissue
lysate from brain samples at 4oC overnight. Then, the IgG magnetic beads are
incubated with the solution containing 0.4ug of the Protein Tech anti-human NINJ2
antibody at Room Temperature for 1 hour. The protein G molecules on the surface of
the beads link the heavy chains of the antibodies using affinity binding. The antigens
and antibodies are then dissociated from the beads with an elution buffer consisting of a
low-pH elution buffer (1M Glycine pH 2.4). The purpose of using this elution buffer is to
separate the antigen from the complex without also obtaining a signal from the antibody.
Once proteins are eluted out from the solution, The glycine elution is then mixed on a
1:1 ratio with the RIPA buffer. This was placed in the Laemmli buffer and heated at
60oC for 20 minutes prior to loading into the protein gel.

0.08ug of P.Tech a-NINJ2

antibodies in blocking buffer is then used to detect the precipitated NINJ2 antigens from
the elution.
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CHAPTER THREE
EXPRESSION PROFILE OF NINJ2 AFTER A
STROKE
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INTRODUCTION
A GWAS study reported two SNPs, rs11833579 and rs12425791, 11 kilo-bases
upstream of NINJ2 associated with the risk of ischemic stroke, suggesting NINJ2 is a
candidate gene for stroke (Ikram et al., 2010). These SNPs are not necessarily the
causal variants for the disease.

However, they can be in linkage disequilibrium to the

causal SNPs in a nearby region of NINJ2, such as in the promoter, the non-coding
intronic site; and/or the open reading frame of the gene. NINJ2 is especially interesting
due to its high degree of homology with adhesion molecules linked to anti-inflammatory
response and tissue remodeling.

NINJ2 also follows a functionally relevant

neuronal/glial expression pattern following a sciatic nerve injury in rats (Milbrandt et al.,
2000). This suggests that NINJ2 may contribute to the development, pathology, and/or
recovery of a neurological disorder such as stroke.
NINJ2 has two transmembrane domains (green), two extracellular domains, and
one cytoplasmic domain as shown in figure 3.1a. NINJ2 belongs to a family of proteins
known as nerve injury induced proteins, or Ninjurins. The structural topology is
characteristic of the protein members of the Ninjurin family. Ninjurins are cell adhesion
membrane proteins that promote neuronal regeneration and have been suggested to
mediate the recovery process of an injured nerve in the PNS (Araki et al., 1996; 1997).
Cell adhesion molecules mediate cell-to-cell and cell-to-matrix interactions for the
guidance of cells to a site of injury.

There are two types of Ninjurins: NINJ1 in the

mammalian genome (Milbrandt et al., 1996) and NINJA in Drosophila melanogaster
(Zhang S. et al., 2006). NINJ2 shares conserved hydrophobic regions in the trans-
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membrane domain with NINJ1 and NINJA and a high level of identical sequences with
the extracellular domains of NINJ1 (Fig 3.1a).
NINJ1 mediates the heterophillic adhesion of leukocytes and vascular
endothelial cells during vascular remodeling as well as a response to inflammation in
the CNS. NINJ1 also enhances the apoptosis-inducing activity of leukocytes during
tissue remodeling, suggesting NINJ1 is a major mediator of inflammation (Milbrandt et
al., 2000; Lee H. et al., 2010). Fig 3.1B shows the adhesion motif in the sequence of
NINJ1. NINJ2, however, does not share the same adhesion motif or mode of expression
as NINJ1, suggesting it acts through a different mechanism underlying cell-to-cell
interaction. Milbrandt et al. demonstrate that NINJ2 mediates homophillic adhesion of
NINJ2 expressing cells. A peptide designed against an extracellular motif in the Nterminus domain of NINJ2 significantly decreases the adhesion capacity of NINJ2
expressing Jurkat cells (Milbrandt et al., 2000). Fig 3.1C shows the sequence that
confers the largest adhesion capacity to NINJ2 expressing Jurkat cells as demonstrated
in the adhesion experiments by Milbrandt. This sequence is highly conserved in NINJ1
and in NINJA.
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Homologous NINJ2 and NINJ1
Transmembrane domains

A

NINJ2 Extracellular (NH2 and CH3) domains are labeled in
navy blue. Cytoplasmic domain is labeled in purple.

hNINJ2
hNINJ1

B
hNINJ2
hNINJ1
NINJ1 adhesion function mediating heterophillic binding
NINJ2 sequence containing
potential adhesion motif
mediating homophillic binding

C

hNINJ2
hNINJ1

D

mNINJ2

hNINJ2

Figure 3.1 Protein sequence, homology, topology, and potential adhesion
functions of NINJ2 and NINJ1. Transparent boxes demonstrate 100% identical
sequences between the proteins. Figure 3.1 shows the hit of positive identical amino
acid sequences between human NINJ2 and NINJ1 (52% identity) using the protein
BLAST function (Altschul S. et al., 1997).

The sequence of NINJ2 with the highest homology to NINJA in Drosophila is
shown in Figure 3.2 and it includes the proposed adhesion motif for NINJ2. NINJA
mediates the adhesion of S2 cells and is essential for tissue remodeling of the tracheal
system in Drosophila. This process is auto-regulated by the ENT domain of the same
protein.

First, the ENT domain of NINJA is cleaved by MMPs.

Then, the ENT

sequence signals the loss of adhesion of S2 cells and ends the process of tissue
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remodeling (Zhang S. et al., 2006). Moreover, the same protein sequence as the one
shown in Figure 3.2 also shows a similar pattern of homology with NINJ1 (Data not
shown).

The high degree of homology in the ENT domain in the three Ninjurins

suggests that the adhesion motif of NINJ2 confers an important biological function.
hNINJ2

dNINJA

Figure 3.2 Protein sequence, homology, and topology of NINJ2 and NINJA. Figure
3.2 shows the sequences of human NINJ2 and Drosophila NINJA. It also shows the
predicted intracellular domain (green bar) and 39 amino acids of the extracellular Nterminus (ENT) domain (blue bar) of NINJA and NINJ2. The intracellular domains are in
a similar location. Most of the homology lies in the extracellular domain of NINJ2 and
the extracellular region of NINJA as shown above.
Furthermore, NINJ2 is induced in Schwann cells one week after a sciatic nerve
injury in the PNS of rats (Milbrandt et al., 2000).

Schwann cells myelinate axons of

motor and sensory neurons in the PNS. Schwann cells also aid in the regeneration of
axons following axonal disintegration in the distal nerve stumps. This is evidenced by
the retardation of axonal growth after the extraction of NMSCs cells in the distal stump
of the peripheral nerve injury (PNI). Following an injury, Schwann cells dedifferentiate
into immature Schwann cells that resemble the adult non-myelinating Schwann cells
(NMSCs). NMSCs then proliferate and aid in the regeneration of injured axons (Fu S.Y.
et al., 1997). This is of significance since the highest level of NINJ2 expression is seen
in NMSCs and promyelinating Schwann cells distal to the site of injury (Milbrandt et al.,
2000).
Schwann cells that myelinate large diameter axons develop into myelinating
Schwann cells while those that myelinate small axons remain as NMSCs (Pereira J.,
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2009). Following an injury, Immature Schwann cells interact promiscuously with many
axons but eventually turn into promyelinating Schwann cells. Promyelinating Schwann
cells wrap around one axon at a time. This process is mediated by the epidermal
growth factor receptor-Neuregulin 1 (ErbB-NRG1) signaling pathway (Raphael AR. et
al., 2011).

Myelination by Schwann cells facilitates faster conduction velocities in

axons (JEssen K. et al., 2010), induces mitochondrial activity in myelinated axons
(Zambonin J. et al., 2011), and stabilizes the point-to point connectivity during the
branching process of developing neurons (Griffin JW et al., 2008).
NINJ2 also seems to mediate the adhesion of NMSCs to unmyelinated nerve
fibers (Milbrandt et al., 2000). After an injury, NMSCs position themselves closer to the
cell bodies of unmyelinated nerve fibers with the aid of adhesion molecules. Once
NMSCs are stabilized in the area of injury, they extend their processes onto
unmyelinated fibers and signal other denervated glial cells to adhere onto these cells.
This aids in the regeneration of damaged nerves through the differentiation of NMSCs
into myelinating Schwann cells (Griffin JW et al., 2008 and Joung et al., 2010).
Unmyelinated axons of small diameter, including C fibers nociceptors, instead, wrap
inside invaginations formed by NMSCs, also known as Remak bundles (Murinson BB et
al., 2005).

These fibers retain a higher degree of plasticity and a larger capacity to

sprout collaterally throughout these processes of regeneration (Vlader A. et al., 2011).
NINJ2 is not known to be expressed specifically in Remak bundles. However, given
that the highest level of induction of NINJ2 is distal from the site of injury (Milbrand et
al., 2000), it is suggested that its induction in NMSCs is crucial for the regeneration of
peripheral unmyelinated nerves in Remak bundles. Furthermore, the role of NINJ2
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expression in the CNS is not well understood. The gene expression of NINJ2 is lower in
human and rat brains than in other tissues, such as in the bone marrow, as indicated in
figure 3.3 (NCBI’s Unigene dataset) and Milbrandt et al., 2000, respectively.

For

instance, NINJ2 is expressed at a relatively lower level in normal brain samples than in
the lung.

Figure 3.3 Expression level of human NINJ2 from Northern blot data across
normal and cancer human tissues (CGAP datasets from Hs.frequencies and
Hs.libraries). Data show the ratio of “the number of appearances of SAGE [NINJ2] tags
divided by the total number of tags in that particular tissue” normalized by 1.2 M
(www.genecards.org/info.shtml#expression_images).

NINJ2 has also been shown to be expressed in the radial glia, also known
Bergmann cells, in the developing brain (Milbrandt et al., 2000). This suggests NINJ2
may play a role in a similar regenerative phase following an injury in the CNS. This is
evidenced by the relatively high level of expression of NINJ2 in the spinal cord and the
induction of neurite extension from tissue cultures of the dorsal root ganglion (DRG) by
NINJ2 expressing cells in vitro (Milbrandt et al., 2000). NINJ2 may affect how the
sensory system in the PNS responds to an injury in the CNS following a stroke.

A

deficiency in the function of the sensory system in the PNS, for instance, is
characteristic of loss of sensibility in stroke patients.

Moreover, there is a higher
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coverage of Schwann cells onto efferent spinal cord fibers than on afferent fibers from
the DRG (Murinson and Griffin, 2004). Thus, a deficiency in the adhesion of Schwann
cells to unmyelinated nerve fibers may lead to the reduction of the sensory capability of
efferent unmyelinated fibers (Vlader A. et al., 2011).

This may result from a reduction

in the expression of molecules like NINJ2 at acute phase of injury (Milbrandt et al.,
2000). Further research is needed on the molecules that mediate the transition from
neural degeneration to recovery.

\
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EXPERIMENTAL RATIONALE
This study uses an induced mouse model of a Middle Cerebral Artery occlusion (MCAo)
in order to determine the changes in expression of NINJ2 after a stroke in mice brains.
The mouse sequence of NINJ2 (mNIN2) is 73% identical to the human sequence of
NINJ2 (hNINJ2) as shown in figure 3.1D. The tissues taken for analysis include cortical
tissue with the focal lesion of stroke as well as the surrounding penumbra.
Experimental samples include RNA and tissue lysates from cortical tissues of ipsilateral
brain hemispheres of the MCAo induced mice. The internal controls for qPCR include
cortical tissues from three healthy mice brains.

Tissues are extracted from stroke

induced mice 3 hours, 24 hours, 3 days, 1 week, and 2 weeks following reperfusion.
This timeline is representative of the injury and recovery stages following the stroke.
Research aims and hypothesis
Aim 1: Quantify changes in gene expression of NINJ2 after a stroke.
AIM 2: Quantify changes in protein levels of NINJ2 after a stroke
Hypothesis: Gene and protein expression of NINJ2 changes as a result of stroke.
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RESULTS
Calculation of the Amplification Efficiency as a measure of probe
sensitivity TaqMan assays. In order to determine the sensitivity of the TaqMan qPCR
assays, relative quantification (RQ) of NINJ2 expression was measured by the
comparative Ct (2-•

C’

T)

method.

This method presumes that the amplicon specific

amplification efficiencies of the qPCR assays are calculated a priori. The amplification
efficiencies (E) and percent efficiencies (%E) are calculated using Equations 1 and 2 in
the methods section (Rasmussen, R. 2001). QPCR amplification efficiency is tested by
performing a serial dilution of cDNA templates extracted from naïve cortical brain
samples. Each sample is tested in triplicate. The details of the testing results for each
qPCR experiment are shown in Table A1 in the appendix. Each of our qPCR
experiments allows for a maximum of three serial dilution points. An efficiency value of
2 also indicates strong probe sensitivity for the target sequence at the range of the input
cDNA concentrations (1000ng to 0.1ng).

The probe efficiency and sensitivity is also

tested and verified by performing four independent serial dilution experiments with eight
(first two reactions) and four (second two reactions) serial dilution points using the same
cDNA template stock. The slope of the dilution curve is determined by plotting Ct
values as a function of the log of the cDNA input concentration values.
The qPCR amplification efficiency results for the NINJ2 and RPOL2 probes are
shown in Figure 3.3. Figure 3.3 demonstrates that the NINJ2 and RPOL2 probes are
sensitive up to approximately 36 and 34 cycles of PCR amplification, suggesting
accurate CT values at a wide dynamic range of input cDNA concentration. The assay
efficiencies are assessed by the slopes of the standard dilution curves, as indicated in
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figure 3.3. The efficiencies are 1.93 and 1.98 for NINJ2 and 1.96 and 1.99 for RPOL2.
The % efficiencies are 92.7% and 98.1% for NINJ2 and 96.3% and 98.6% for RPOL2.
The efficiencies of both assays are within 10% difference from each other.

This

demonstrates their performance in the qPCR reactions and permits the implementation
of the 2-•



T method

for the relative quantification analysis. The amplification results for

INOS2 are shown Figure A.3 in the appendix.

The slopes of the standard dilution

curves for the two NINJ2 assays are -3.5 and -3.4. The slopes of the standard dilution
curves for the two corresponding RPOL2 assays are -3.41, and -3.36. The correlations
observed between the log amount and resultant CT values for each probe assay are
strong. All of the regression coefficients (R2 values) are greater than 0.99.
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Figure 3.3 Determination of QPCR efficiencies of target gene (NINJ2) and
reference gene (RPOL2). Ct values (y-axis) versus the log of cDNA concentration (xaxis) are plotted in order to calculate the slope. Each standard curve represents an
independent experiment.

42

Timeline of Expression of NINJ2 in cortical tissues of MCAo Stroke induced
mice brains and validation of results by the expression profile of INOS-2.
Increasing NINJ2 gene expression 7 days after stroke in the ipsilateral
cortical tissues of MCAo mice brains. In order to determine changes in the gene
expression of NINJ2 and INOS2 due to an induced MCA occlusion in mice, three
primary ischemic (ipsilateral) cortical tissues and three matched control (contralateral)
cortical tissues are evaluated at five time-points (3hours, 24hours, 3days, 7days, and
14days) after reperfusion. cDNA is pre-amplified and tested for relative changes in the
mRNA levels of NINJ2 and INOS-2 using the comparative Ct method. RQ values are
normalized to changes in the expression of RPOL-2 housekeeping gene and compared
with the expression of NINJ2 in cortical tissues of healthy mice brains. Figure 3.4
demonstrates changes in the induction of NINJ2 in the ipsilateral and in the contralateral
cortex. The details of the calculations and test results are shown in figure A.6 in the
appendix. There is no significant change in NINJ2 gene expression in the contralateral
cortical tissue at any time point although there is a slight decrease in expression at 24hr
after stroke, which did not reach statistical significance (P=0.06). In the ipsilateral
cortical tissues, there was a significant induction in NINJ2 expression at 7 days (2.2
fold; P=0.007), which is slightly attenuated at 14 days (1.9 fold; P=0.07).
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Figure 3.4 Pattern of expression of NINJ2 in the ipsilateral and contralateral cortical
tissues of MCAo brains compared with expression in healthy mice brains (naïve). The
red asterisk indicates a significant fold induction (2-
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Increasing expression of INOS2 3 days and 7 days after stroke and
maximum induction of expression at 3 days after stroke.

In order to validate

changes in the expression profile of genes induced after a stroke, we also study
changes in the expression profile of an inducible gene (INOS-2) that is up-regulated as
a result of post-inflammatory processes from a stroke.

Figure 3.5 demonstrates

changes in the fold induction of INOS2 in the ipsilateral cortex. The details of the
calculations and test results are shown in figure A.6 in the appendix.

There is no

significant change in INOS2 gene expression in the contralateral cortical tissue at any
time point. In the ipsilateral cortical tissues, there is a significant induction in INOS2
expression at 3 days (3.5 fold; P = 0.05) and 7 days (2.2 fold; P=0.05).
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Figure 3.5 Pattern of expression of INOS2 in the ipsilateral and contralateral
cortical tissues of MCAo brains. The red asterisk indicates a significant fold induction (2• C’T) of INOS2 in the ipsilateral tissues. The blue number sign indicates a significant fold
induction of INOS2 in the contralateral tissues. The data points for the time-point results show
the average of RQ compared to the naïve samples from the same qPCR experiments.
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Characterization of the specificity of an anti-human NINJ2 antibody for the
study of changes in the levels of NINJ2 protein molecules in cortical tissues
of mice brains after stroke.
Selectivity of the a-NINJ2 Antibody in detecting the 23 KD band in the
mouse brain, lung, and 293+NINJ2 cell lysates. In order to detect changes in the
levels of the protein molecules of NINJ2 after stroke, it is necessary to acquire an
antibody that detects NINJ2 in the mouse brain and in positive controls that overexpress the NINJ2 gene. The molecular size of NINJ2 (23KD) is originally reported in
over-expressing Chinese Hamster Ovary (CHO) cells by Milbrandt et al., 2000.

The

positive controls consist of protein lysates from mouse lung tissue and NINJ2 overexpressing 293-T cells. In figure 3.7, we report the detection of the molecular size of
NINJ2 (23 KD) in 80 µg of mouse brain and 30 µg of lung tissue lysate as well as in cell
lysate of NINJ2 over-expressing 293-T cells by a commercially available antibody from
Protein Tech Inc.

It shows the detection of a protein signal at 23KD in both the whole

homogenate and supernatant fractions of the brain and lung tissues. The antibody
detects higher levels of protein in the whole tissue homogenate than in the supernatant
fraction of the lung tissue.

The whole tissue homogenate lysate carries a high

concentration of membrane proteins, thus improving the chance for its detection of the
membrane NINJ2 protein. The results also demonstrate the presence of the 20 KD and
16 KD bands in the lane using the 293+NINJ2 cell lysate.
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Figure 3.6: Detection of mouse brain and lung proteins with a molecular size of
23 KD by the Protein Tech a-NINJ2 Ab. Samples include mouse brain (first two
lanes), mouse lung (lanes 3 and 4), and human 293-T cells transfected with human
NINJ2 cDNA.
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Specificity of the P. Tech antibody in detecting the NINJ2 protein at 23KD in the
mouse brain cortex. In order to assess the specificity of the antibody to recognize the
proteins of NINJ2 at 23KD in cortical brain tissues and 293+NINJ2 transfected cell
lysates, a peptide competition and an immunoprecipitation assay are performed. The
purpose of these experiments is to reduce the possibility of obtaining a false positive
result at 23KD. The experimental lane is run alongside the negative control lane and a
protein ladder in the gel. The reduction in the signal of a band in the experimental lane
compared to the control lane is indicative of the selectivity of the antibody against the
target protein. Figure 3.7 uses protein lysate from brain, lung, and transfected cell
lysate and it shows significant reduction in the protein level at the 23KD band from the
lung and 293+ lysate. Figure 3.7a shows the disappearance of the 23 KD band in the
mouse brain tissue after 200X molar peptide incubation with the P. Tech antibody for 1
hour at room temperature. Figure 3.7 b shows a slight reduction in the band intensity of
the brain while figures 3.7 (c and d) show a significant reduction in the band intensity of
the lung and 293+NINJ2 lysates after antibody-peptide incubate overnight at four
degrees Celcius. This suggests that the temperature changes the conformation of the
NINJ2 antigenic site in the antibody, and thus prevents it being exposed to the peptide,
as when it is performed at room temperature. This figure suggest for the competition of
the antigen binding site in the NINJ2 antibody.
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A

B

C

D

Figure 3.7: Results from the peptide competition experiment using mouse cortical
brain tissue (A AND B), lung and 293+NINJ2 transfected cell lysates (B AND C).
Commercially acquired peptides (Santa Cruz sc-79653) mapping membrane domain of
the NINJ2 protein sequence is used to compete for the antigenic site of the P. Tech aNINJ2 antibody. The peptide competition experiments are performed using protein
lysate from the mouse brain and lung tissues and 293+ NINJ2 transfected cells.
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Validation of the specific nature of the antibody by its ability to immunoprecipitate the NINJ2 protein at the 23KD band.

In order to verify the

immunogenicity of the P. Tech antibody to the whole sequence of the NINJ2 protein at
23 KD, we tested the ability of the antibody to immuno-precipitate (IP) the NINJ2
antigen from the mouse brain and 293+NINJ2 transfected lysates.

The P. Tech

antibody is tested for its specificity to detect the NINJ2 antigens in the protein lysate
solution.

The immunoprecipitation assay consisted in incubating the antibody

molecules-bound to magnetic beads coated with protein G- with protein lysates. For
every IP experiment, a negative IgG antibody raised in rabbits is used in order to
differentiate the background bands from the specific band detected by the a-NINJ2
antibody.

A low stringent solution is then used to separate the antigens from the

antibody and preserve the structural conformation of the protein as much as possible.
We use silver staining of the antigens isolated from the protein lysates to validate the
specificity of the antibody. Figure 3.8 shows silver staining of a protein gel loaded with
the precipitated sample from the experimental and the negative IgG control lane. It also
shows the isolation of the 23 KD band, along with other non-specific bands at higher
molecular sizes.

Figure 3.9 also detects the precipitation of the 23 KD band in the

experimental lane of the membrane blots from the 293+NINJ2 and brain lysate
solutions. The results in the first lane of each blot in figure 3.9 indicate a detection of
different protein sizes, including a molecular size at 23 KD corresponding to the band of
the NINJ2 protein. The control IgG is also immunoreactive to proteins at the same
molecular size although at much lower levels.

It also shows two other bands at 31KD

and 38KD. Both results suggest that the P. Tech antibody selects for the NINJ2 protein

51

at 23KD out of all the other non-specific protein bands in the brain tissue lysate and the
positive 293+NINJ2 control.

Figure 3.8: Silver staining of the immuno-purified
antigens
from
the
immunoprecipitation
experiment with the mouse brain tissue.
In the
first lane, the P. Tech NINJ2 antibody is used to purify
the NINJ2 antigen from the brain sample. In the
second lane, the IgG control is used to validate the
reactivity of the P. Tech antibody to NINJ2 in the brain
sample. The IgG control is obtained from the same
species (rabbit) where the P. Tech antibody is raised
in. The silver staining is performed on a protein gel
that carries the immuno-purified brain sample
concentrated with the NINJ2 antigen.
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Figure 3.9: Detection of the 23KD band by immunoprecipitation of the NINJ2
molecules from protein lysates of the 293+NINJ2 transfected cells and mouse
brain samples. The antigen is purified using the P. Tech Antibody as described in the
methods section for IP. The first lanes of each blot represent the purified NINJ2 antigen
from the 293+ transfected lysate and the brain lysate samples. The second lanes of
each blot represent the control IgG used in the IP experiments.

Increasing protein levels in the contralateral and ipsilateral cortical tissues at 7
and 14 days after stroke.
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In order to assess changes in the protein expression of NINJ2 due to an induced MCA
occlusion in mice, three primary ischemic (ipsilateral) cortical tissues and three matched
control (contralateral) cortical tissues are evaluated at three time-points (24hours,
7days, and 14days) after reperfusion.

Tissues are homogenized in tissue lysate (1X

RIPA) solution to test for changes in the protein levels of NINJ2 with western blotting.
The relative densities of light intensities (RD values) of the protein bands detected at
23KD by the P. Tech antibody are normalized to changes in the RD values of the
protein standards. The standards consist of B-Actin bands at 42 KD (as shown in the
second rows of the immuno-blots in fig3.10). The resultant values are reported as
normalized relative densities (NRD) and are compared against the NRD values of the
cortical tissues of a naïve mouse brain. Figure 3.10 indicates an increase in the protein
levels of NINJ2 in the ipsilateral brain cortex 7 days (4.5 fold) and 14 days (4 fold) after
a stroke. It also shows an induction in the protein levels of NINJ2 in the contralateral
tissues 7 days (6.5 fold) and 14 days (4 fold) after stroke. Because of the low number
of animals for which results are obtained, it is chosen present averages without
standard deviations.
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Figure 3.10: Changes in the protein levels of NINJ2 in mice brains following a
stroke. The results show an increase in the levels of the 23KD band corresponding to
changes in the NINJ2 protein levels in the ipsilateral cortical tissues of mice brains
7days and 14 days after stroke. It also shows an increase in NRD values of NINJ2
protein expression in the contralateral cortical tissues 7days and 14days after stroke.
These results are produced from the tabulation of the normalized relative density ratios
obtained in the western blot procedures. The results indicate a higher induction of
protein expression in the contralateral than in the ipsilateral cortical tissues tissues.
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DISCUSSION
A Genome-wide Association Study (GWAS) from four large prospective cohorts
in the USA and Europe identified an association of two Single Nucleotide
Polymorphisms (SNPs) on chromosome 12p13 with a greater risk of ischemic stroke in
individuals of European and African-American ancestry. This generated a hypothesis
regarding a potential candidate gene for stroke.

The GWAS reports data on the

association of SNPs to greater susceptibility of stroke. The GWAS-detected SNPs are
located 11 Kb upstream of the Ninjurin 2 (NINJ2) gene. Many weakly associated SNPs
are located within the coding and promoter regions of NINJ2 (Ikram et al., 2010). This
has led us to hypothesize that the causal SNP for stroke may be related to NINJ2
function. If the causal SNP is located in a regulatory and/or a functional region of
NINJ2, it may result in the alteration of the expression and/or function of the gene. This
change may alter the susceptibility for the disease and/or worsen the progression of the
disease. The SNP is associated with a greater susceptibility to incidence of stroke.
Changes in expression are evaluated following a time-course of five time-points
(3hours, 24hours, 3days, 7days, and 14days) after reperfusion. Data suggest a 2.3-fold
induction in NINJ2 gene expression in the ischemic core and the peri-infarct tissue to
the ischemia (Ipsilateral) cortex at 7 days after stroke, which persists at 14 days.
In order to clarify the possible role of NINJ2 in stroke, we sought to determine
whether there will be changes in the expression levels of NINJ2 in the ischemic brain
cortex of a transiently induced mouse that models a focal Ischemic stroke in humans.
This model permits the record of behavioral as well as biochemical changes as mice
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progress from acute to the recovery stages of stroke. Changes in expression of NINJ2
are reported following a stroke.
GWAS discovered a SNP with greater risk to a clinically recognized onset of
stroke. Our results demonstrate changes in expression of NINJ2 following a stroke.
The induction of expression of NINJ2 at 7 days suggests NINJ2 plays a role as a
molecular mediator of recovery. However, further functional experiments are needed,
i.e. knocking out NINJ2 in the mouse and inducing it with stroke, in order to establish
the role of NINJ2 in the recovery phase of stroke. Our results suggest that expression
of NINJ2 in the cortex may be associated with a delayed onset of stroke. Therefore, it is
necessary to determine an association between the frequencies of SNP with the time of
onset of stroke. Furthermore, the GWAS does not take into account clinically
unrecognized mini-strokes that may occur over the life-time of an individual. Based on
our results, if the gene plays a role as an endogenous recovery mediator of stroke,
individuals over-expressing the gene after a mini-stroke may be less susceptible to an
early onset of a bigger stroke. NINJ2 may also be transcriptionally suppressed in
people with greater susceptibility to an early onset of stroke. It will also be of interest to
perform a GWAS between the SNPs and the expression of NINJ2 in people with time of
onset of stroke. This may determine a functional interaction between NINJ2 and other
genes involved in susceptibility to delayed onset of stroke. Also, it is hypothesized that
attenuation in the expression of the gene may result in less protection from cortical
damage by the stroke. Those with an over-expression of the gene may be protected
from damage to the cortical tissue as a result of stroke. Thus, attenuation in the
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expression of NINJ2 may be indicative of greater susceptibility to a greater damage
from the stroke.
A potential contribution of NINJ2 to stroke can be deduced from the biological
pathway of genes with similar gene expression profiles as NINJ2 (Hughes T.R. et al.,
2000).

The temporal expression profile of NINJ2 is similar to the pattern of expression

of NINJ2 and NINJ1 following a transected and crush sciatic nerve axotomy.

The

pattern of expression of NINJ1 following a sciatic nerve axotomy shows that it is upregulated beginning at 16 hrs after injury (Araki et al., 1996).

Data for NINJ2 in the

same model shows that it is up-regulated beginning at 7 days after injury. Both in NINJ1
and NINJ2 level of expression reaches peak levels 7-14 days after the injury and remain
elevated for up to 56 days after injury (Milbrandt et al., 2000).

The induction of

expression of the Ninjurin genes occurs in the segment distal to the injury after either
transection or crushed.

NINJ1 mediates leukocytes recruitment in the cerebral

vasculature after inflammation. This response to inflammation is also known to take
place at the acute phase of stroke (Lee, Hyo-Jong et al., 2010).

Since the gene

expression of NINJ2 is not significantly altered at this stage, NINJ2 may not be involved
in this humoral process of inflammation. NINJ2 also doesn’t share same adhesion motif
as with NINJ1.

However, both NINJ1 and NINJ2 facilitate the neurite outgrowth from

peripheral motor neurons. This suggests that NINJ2 is active and performs the same
function as NINJ1 at later time-points following injury. This may be a reason why NINJ2
may not be involved in the humoral response in the acute phase of stroke (Lee, HyoJong et al., 2010).

Our data supports the notion that NINJ2 is relevant to recovery

mechanisms distal to an area of stroke.
58

NINJ2 is also induced in Schwann cells at the late stages of recovery from a
nerve injury in rats. Schwann cells are glial cells that over-express NINJ2 at the early
stage of maturation and those with no myelination capacity. These cells support neural
regeneration from an injury in the PNS by adhering to and facilitating conductivity in
neurons, suggesting NINJ2 plays some role in the repair of nerve damage. NINJ2 is
also found to be constitutively expressed at low levels in radial glia in the CNS
(Milbrandt et al., 2000). This indicates that NINJ2 is expressed in cells at early stages
of maturation and may play a role in the cellular response to a disease.
The gene pattern of expression of NINJ2 is also similar to the pattern of
expression of the nerve growth factor (L1) and neural cell adhesion molecule (N-CAM)
after injury.

These adhesion molecules facilitate the cell-to-cell interactions between

Schwann cells and neuronal axons following a sciatic nerve injury in the PNS. The
expression of L1 and N-CAM is induced in non-myelinating Schwann cells one week
after the injury.

The time course of expression following sciatic nerve injury is similar

to that of NINJ1, neural CAM, and L1 following a transected sciatic nerve axotomy.
Adhesion molecules such as MCAM or L1 also enhance neurite outgrowth in the same
manner as NINJ1 and NINJ2 (Milbrandt et al., 2000). Given this pattern of expression,
NINJ2 protein may be classified as molecule involved in the recovery process of nerve
regeneration in the peripheral nervous system as well as in the central nervous system
after stroke.
Data also suggest an increase in the protein levels of NINJ2 in the Ipsilateral and
contralateral tissues at 7 days, which also persists at 14 days. The significant injuryinduced induction of the mRNA and protein levels occurs at 7 days.

Furthermore,
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there seems to be a larger production of the NINJ2 protein in the contralateral
compared to the ipsilateral cortical tissues. This is not consistent with the gene
expression results since mRNA levels do not show a significant change in the
contralateral tissues.

Data from peptide competition and immunoprecipitation assays

seem to suggest that the 23 KD band corresponds to the NINJ2 protein. As suggested
from the peptide competition results, the antibody binding site of the Protein Tech
antibody is competed against a peptide mapping within the membrane domain of the
mouse NINJ2 sequence. Data indicate a very slight decrease in the light intensity of the
band at 23 KD in brain in the presence of the peptide when exposed at 4oC (fig 3.7b).
This suggests that the binding site of the antibody does not confer a high degree of
affinity to the epitope mapping a membrane region of NINJ2, assuming equal loading.
The evidence that results obtained from antibody-peptide incubation at 4oC is not due to
chance, is the significantly higher competition with NINJ2 that is shown in the lung and
transfected lysates (figs. 3.7c and d). A possible reason for the inconsistency in the
peptide competition results with NINJ2 antigens in the brain, lung, and transfected
lysates may be due to the low expression of the protein in the brain. The sample in the
brain tissue lysate would expose less amount of the NINJ2 protein for the antibodypeptide interaction. The immunoprecipitation assay also provides an indirect evidence
for the identification of the NINJ2 protein at 23 KD, as suggested by Figure 3.8.
A limitation of the antibody characterization study is that we have no direct proof
that the 23 KD band corresponds only to the NINJ2 molecule.

For instance, the

immunoprecipitation study only offers indirect evidence suggesting that the Protein Tech
antibody detects NINJ2 at 23KD but it does not rule out the possibility of it also
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detecting an identical protein such as NINJ1. It may be that the Protein Tech antibody
is detecting both NINJ2 and NINJ1 proteins in the samples.

In fact, Araki et al. report

the molecular weight of NINJ1 also to be at 22 KD. Thus, it may be that the a-human
NINJ2 antibody from Protein Tech also detects the mouse form of NINJ1 (Araki et al.,
1997).

This antibody may be recognizing epitopes specific in NINJ2 as well as in the

NINJ1 proteins in the membranes.
A temperature of 4 oC is maintained for all the incubation steps with the Protein
Tech antibody throughout the experiments.

These include the protein transfer and

membrane incubation steps in the western blot experiment; the peptide incubation step
in the peptide competition assay; and the brain tissue lysate incubation in the
immunoprecipitation experiment. The cold temperature may be maintaining the nonlinear structural conformation of the NINJ2 protein, thus exposing the structural epitopes
for their detection by the Protein Tech antibody. However, this conformation may also
be preserved for other homologous proteins, such as NINJ1. The antibody from Protein
Tech is raised against the whole recombinant protein of NINJ2, thus increasing the
likelihood of detecting small differences in structural conformation in the proteins.
Consequently, this may induce the cross-reactivity by the Protein Tech antibody with
NINJ2 and NINJ1. Another reason why the antibody may be detecting NINJ1 in the
samples is that the pattern of expression of NINJ1 at 7 days after sciatic nerve injury is
similar to that of NINJ2 (Araki et al., 1997).
If the pattern of expression of the 23 KD band corresponds only to changes in the
NINJ2 protein, then it is suggested that the NINJ2 protein levels are increased as part of
an unknown recovery mechanism from stroke. For instance, NINJ2 may mediate the
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adherence of molecules in the induction of anti-inflammatory processes in the brain.
This suggests for a global increase of protein expression of NINJ2 in the brain cortex 1
week after stroke. The gene expression is up-regulated in the ipsilateral cortex while
the protein levels increase in the contralateral cortex 7 days after stroke. The gene
expression of NINJ2 is un-regulated in the contralateral cortex. It may be that posttranscriptional event down-regulates the expression of NINJ2 in the contralateral tissue.
This would seem to suggest that once the NINJ2 protein molecules are produced in the
penumbra, these then trans-locate from the injured cortex to the healthy hemisphere,
where it maintains an induced level at the late recovery stages following stroke.
Moreover, the protein levels of NINJ2 may be significantly higher in the
contralateral cortex after stroke where synaptic plasticity is known to occur.

Thus,

NINJ2 may have additional synergistic effect on synaptic plasticity in the contralateral
cortical tissue of the brain after stroke. In order to assess the significance of changes
protein levels at this time-point, it is necessary to include more mice in the experiments.
However, it is not possible to conclude about the biological significance of changes in
the protein levels as a result to stroke. This is due to one of the major limitations of our
study, the fact that we don’t have an antibody that is only specific for the mouse NINJ2
protein.

62

CONCLUSION
A GWAS study has found two SNPs associated with greater susceptibility to
incidence of ischemic stroke in the general population. These SNPs, located upstream
of the NINJ2 gene, are not necessarily the causal variants of the disease. If the causal
SNP is located in a regulatory and/or a functional region of NINJ2, it may result in the
alteration of the expression and/or function of the gene. We have characterized the
pattern of expression of NINJ2 in the brains of MCAo induced mice models at different
time points following a stroke. The NINJ2 pattern of expression suggests that it may be
induced at the late-time phases after stroke. Although a larger number of animals are
needed at 1week and 2weeks time-points, our results are consistent with experiments
that demonstrate a similar pattern of expression following sciatic nerve injury in the
peripheral nervous system.

Therefore, it is hypothesized that any change in the

expression of the gene that may be induced by the causal SNP in the population may
be of significance for the recovery of the disease. Thus, it will be of good interest to
perform deep sequencing of this region to look for the causal variant of stroke in the
population. It may also be beneficial to study changes in the expression of NINJ2 in
brains of post-mortem ischemic stroke patients carrying the SNPs associated with
greater risk of stroke in order to correlate the findings in mice with humans. A change in
the expression of NINJ2 in human brains will be a valid parallel comparison to the
known changes observed in mice brains.
It is hypothesized that the knockout of Ninj2 may increase the susceptibility of
brain damage due to ischemic stroke. An animal model that has being genetically
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modified permits the analysis of the biological mechanisms underlying the cause for the
disease (Bonthu S. et al., 1997). If shown to increase susceptibility to damage in the
brain of the Ninj2-KO mice, Ninj2 could be classified as a major molecular target that
contributes to neuroprotection (a.k.a. neurovascular remodeling). It is also suggested
that NINJ2 gene is an endogenous target of recovery that is silenced by unknown
mechanisms that could be associated with the stroke-associated SNPs in the
population. Elucidating these mechanisms can be beneficial for the design of personal
medicine for the prevention of stroke in patients with high probability of developing the
disease. This study provides a better understanding for the involvement of NINJ2 in
stroke.
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APPENDIX
PREPARATION OF SOLUTIONS
Master-Mix preparation for cDNA production -

A master mix including all the reagents

from the following table was prepared in ice.
Table

A.1

Preparation

It is considered more

of

the

cDNA

reaction

from

10X RT Buffer

2.0 µl

25X dNTP Mix (100uM)

0.8 µl

10X RT Random Primers

2.0 µl

Multiscribe R. Transcriptase

1.0 µl

Nuclease-free H2O

4.2 µl

Total

9.0 µl

a master mix for all

the

ABI

RT

Kit

accurate to prepare
the

reactions

prepared in that day. For instance, if all the 19 brain RNA samples are used that day to
make cDNA, then a master mix of 19 + 10% of 19 +1 samples are prepared. This
master mix is enough to prepare 21 cDNA samples.
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qPCR Analysis– The 7900 ABI qPCR instrument yields a CT value for each well in 96well plate. The CT values are transported to our spreadsheet template in Microsoft
Excel linked to the templates in Figure A.2.

Our qPCR analysis program in Excel

performs further analysis on the CT values. This design permits the user to input the
desired amount, the identity of the gene, and the timeline of experimentation in an Excel
worksheet. The program automatically connects this information into a printable design
for qPCR plate. Our plate format follows the requirements for an RQ analysis. These
plates are color coded so as to represent a sample ID with a different color. The 3 days
sample is repeated in both plates in order to maintain consistency between the timepoints. This worksheet uses the same format as the one provided by the ABI
instrumentation, thus facilitating data analysis.

Figure A.2 shows 96-well plates

designed using advanced functions in Excel.
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Figure A.1: Automated qPCR plates (Injury and Recovery) designed using Excel.
cDNA Input – The same cDNA aliquots are used for the rows corresponding to the
target gene (rows A – D) and the endogenous gene (rows E – H) probes. For instance,
wells A1-A3 receive both 1µl of cDNA and 8µl of water.
same aliquot are added into wells D1-D3.

cDNA molecules from the

Then, 11 µl of the qPCR master mix

containing 1 µl of the corresponding primer/probe are added onto each of these wells.
In this way, both groups receive equal treatment and the degree of error between
triplicates and gene probes is significantly reduced. The 96-well plate also includes
negative control wells (NTC) wells with the water used in the preparation of the
reactions. These wells signal when the reactions carry contaminants which may
interfere with the results.
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Standard Curve – Figure A.2 shows one example of a standard curve generated by the
SDS software. Its slope is used to calculate the amplification efficiency of RPOL2.

Figure A.2 Standard Curve Plot and Amplification Plot showing a serial dilution with
cDNA from healthy mouse brain cortex. The amplification plot shows a green horizontal
line that indicates where the CT value lies at the exponential phase of the sigmoidal
curves.
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Details of qPCR Amplification Efficiencies per experiment – Table 3.1 shows the qPCR
efficiency data for all the three experimental runs of the target (NINJ2 and INOS2) and
endogenous gene (RPOL2). Most of our data meet the initial presumption of equal PCR
efficiency as required by the • -Ct method.
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Table 3.1 qPCR Amplification efficiencies per qPCR experiment.

A

NINJ2 IPSILATERAL

B

NINJ2 CONTRALATERAL
INJURY PLATE

INJURY PLATE

EXP1
EXP2
EXP3

NINJ2
RPOL2
NINJ2
RPOL2
NINJ2
RPOL2

qPCR Amplification Efficiencies
Sample Slope
log E
E
Naïve
-3.45
0.290
94.82
Naïve
-3.62
0.277
89.03
Naïve
-3.30
0.303
100.79
Naïve
-3.35
0.299
98.91
Naïve
-3.42
0.292
96.08
Naïve
-3.52
0.284
92.45

EXP1
EXP2
EXP3

NINJ2
RPOL2
NINJ2
RPOL2
NINJ2
RPOL2

Naïve
Naïve
Naïve
Naïve
Naïve
Naïve

RECOVERY PLATE

RECOVERY PLATE

EXP1
EXP2
EXP3

C
EXP1
EXP2
EXP3

EXP1
EXP2
EXP3

NINJ2
RPOL2
NINJ2
RPOL2
NINJ2
RPOL2

qPCR Amplification Efficiencies
Sample Slope
log E
E
Naïve
-2.01
0.498
214.79
Naïve
-3.48
0.287
93.79
Naïve
-3.33
0.300
99.51
Naïve
-2.92
0.343
120.20
Naïve
-3.34
0.300
99.38
Naïve
-3.48
0.287
93.67

INOS2 IPSILATERAL

INOS2
RPOL2
INOS2
RPOL2
INOS2
RPOL2

INOS2
RPOL2
INOS2
RPOL2
INOS2
RPOL2

INJURY PLATE
PCR Efficiency
Slope
log E
E
Naïve
-2.290
0.437
173.33
Naïve
-3.220
0.311
104.44
Naïve
-2.060
0.485
205.80
Naïve
-3.520
0.284
92.35
Naïve
-2.220
0.450
182.13
Naïve
-3.520
0.284
92.35
RECOVERY PLATE
PCR Efficiency
Slope
log E
E
Naïve
-3.26
0.307
102.59
Naïve
-3.45
0.290
94.82
Naïve
-3.70
0.270
86.19
Naïve
-3.29
0.304
101.18
Naïve
-3.49
0.287
93.43
Naïve
-3.41
0.293
96.47

PCR Efficiency
Slope log E
E
0.306
102.48
-3.26
0.290
95.05
-3.45
0.306
102.48
-3.26
0.290
95.05
-3.45
-3.40
0.294
97.00
-3.36
0.297
98.27

EXP1
EXP2
EXP3

D
EXP1
EXP2
EXP3

EXP1
EXP2
EXP3

NINJ2
RPOL2
NINJ2
RPOL2
NINJ2
RPOL2

Naïve
Naïve
Naïve
Naïve
Naïve
Naïve

PCR Efficiency
Slope log E
E
0.282
91.37
-3.55
0.292
95.91
-3.42
-3.30
0.303
100.96
-3.50
0.286
93.12
-3.13
0.320
108.86
-3.26
0.307
102.72

INOS2 CONTRALATERAL

INOS2
RPOL2
INOS2
RPOL2
INOS2
RPOL2

INOS2
RPOL2
INOS2
RPOL2
INOS2
RPOL2

INJURY PLATE
PCR Efficiency
Slope log E
Naïve
-3.196
0.313
Naïve
-3.392
0.295
Naïve
0.044 -22.506
Naïve
-3.520
0.284
Naïve
-3.260
0.307
Naïve
-3.520
0.284
RECOVERY PLATE
PCR Efficiency
Slope log E
Naïve
0.000 #DIV/0!
Naïve
#NUM! #NUM!
Naïve
-2.53
0.395
Naïve
-3.42
0.292
Naïve
-3.20
0.312
Naïve
-3.42
0.292

E
105.53
97.14
-100.00
92.35
102.65
92.35

E
#DIV/0!
#NUM!
148.37
95.97
105.24
95.96
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qPCR amplification efficiencies of INOS2 – The results for the qPCR amplification
efficiencies of INOS2 are presented below. These show an efficiency of +/- 100%,
suggesting that the 2-•



T

method can be implemented for the calculation of the RQ of

INOS2 following the timeline after a stroke.

Figure A.3 Independent INOS2 Standard Curve Slope = -3.35 E =

Figure A.4 Independent RPOL2 Standard Curve Slope = -3.47 E =

PCR Efficiency
Slope
log E
E
Naïve
-3.26 0.306748466
102.6508671

PCR Efficiency
Slope
log E
E
Naïve
-3.52 0.284090909

92.3494324

Figu

re A.5 Independent experiments for INOS2 and RPOL2 Standard Curves
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Figure A.6 SAS Results from the mixed model test of statistics. These results demonstrate the adjusted pvalues for the differences in the means of RQ values between time-points. These values control for the
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replicates within the time-points. The values marked in yellow represent those that show significant
differences in gene expression.

PROTEIN ANALYSIS
Mice tagging – Mice are tagged in their ear lobes and a record is maintained with the
time at which the last CBF is measured. The time count starts at this stage for the
subsequent brain dissection.
1X PBS – 1X PBS is diluted from 10X PBS with deionized water.

The 10X PBS is

prepared in 1 liter using the following reagents: 80g of NaCl, 2g of KCl, 14.4 g of
Na2HPO4, and 2.4 g of KH2PO4. The dry chemicals are first dissolved in 800 ml of
dH2O, pH adjusted to 7.4 with HCl, raised the volume to 1 liter, and autoclaved.
12% Electrophoretic Gel – First, 500 ml of 1.5M Tris-Borate (TB) and 500 ml of 0.5M
TB is prepared with distilled water and saved in large glass containers. The 1.5M Tris
Buffer (pH 8.8) is prepared for the resolving gel, while the 0.5 M Tris Buffer (pH 6.8) is
prepared for the stacking gel. The 1.5M Tris Buffer is prepared by adding 90.85 g Tris
into a total volume of 500 ml with dH2O, adjusting the pH to 8.8 with 1M HCl. The 0.5
M Tris Buffer is prepared by adding 30.28 g of Tris into a total volume of 500 ml with
dH2O, adjusting the pH to 6.8 with 1M HCl. Both solutions are stored at 4oC. An
Erlenmeyer flask is used to mix 4.0 ml of 30% acrylamide/Bisacrylamide, 2.5 ml of 1.5
M TB (pH 8.8), 3.35 ml H2O, 100µl of 10% SDS, 50µl of 10% AP, 10µl of TEMED for
the Resolving Gel. The 10% AP is prepared with 0.5 g AP and dH2O to 5 ml and stored
at 4oC for no more than 2 weeks.
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4% Stacking Gel – The 4% Stacking gel is prepared with 0.65 ml of 30%
acrylamide/Bis, 1.25 ml of 0.5M TB (pH6.8), 3.05 ml of H2O, 50 µl of 10% SDS, 25 µl of
10% Ammonium Persulfate (AP), and 5ul of TEMED. The resolving gel is casted first,
then a layer of water is added on top to demarcate the end of the polymerization, and
then the stacking gel is casted on top. The comb is then placed on the stacking gel to
mark the wells for the samples.
4X Loading Stock Solution – To make the 4X stock, 2ml of 0.5M TB (pH 6.8), 0.31g of
DTT, 0.4g of SDS, and 0.002 g of 0.2% Bromophenol Blue, and 2 ml of Glycerol are
mixed in a 15 ml conical tube. To make 1X from 4X stock, the loading buffer is diluted
1:3 times with the sample in RIPA buffer. The final 1X concentration for the loading
buffer reagents are 50mM Tris-HCl, 0.1M DTT, 2.0% SDS, 0.01% Bb, and 10%
Glycerol.
Preparation of Lysis (RIPA) Buffer – (50mM Tris-HCl, 1% NP-40, 0.5% deoxycholic
acid, 0.1% SDS, 1mM EDTA, and 150 mM NaCl).
Making the TBST – The final solution of TBST contains 10mM Tris-HCl, 100 mM NaCl,
and 0.2% Tween 20. These solutions are prepared directly from the stock chemicals as
followed: 1.2 g of Tris-HCl mixed with 5.8g of NaCl and 2ml of Tween 20 all added into
ddH2O to 1000 ml and pH adjusted to 7.4.
Protein Gel Electrophoresis –The first step in the procedure involves running the gel in
Tris-glycine electrophoresis buffer (pH 8.3) at 70V for about 15 minutes, then at 130V
for 2 hours or until the purple/bluish mark from the bromophenol blue reaches the
bottom. The Tris-glycine buffer is prepared with 0.025 M Tris, 0.1 M glycine, and 0.1%
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SDS. Running the gel at a lower voltage prevents the high electric shock to disrupt
some of the most sensitive proteins. As the SDS-coated (negatively charged) proteins
migrate towards the positive end of the gel, they are compartmentalized in holes formed
by a mesh of bis-acrylamide polymers in the gel. The holes are proportional to the size
of proteins. Proteins of bigger size will remain stuck on top of the gel. The Precision
plus Protein Standard (dual color) from BioRad is also used to determine the molecular
size of our protein of interest. Proteins in the gel are then transferred onto a pvdf
membrane for further testing with the antibody.
Protein transfer (part 1)– The transfer of proteins into a membrane involves making a
“sandwich” system with the gel containing the protein samples; as well as the
corresponding pvdf membranes and filter pads, made out of nylon sponge, placed on
either side of the gel. This system runs in an electro-active solution (Tris-buffered saline
+ Tween20 or TBS-T) in ice and in the cold room in order to transfer the proteins onto a
membrane with minimal disruption to the protein structures.
Protein transfer (part 2)– Preparing for the protein transfer procedure requires wetting
the PVDF membrane in 100% methanol for 30 sec and then placing it inside a chamber
with the transfer buffer. The filter pad, as well as the transfer apparatus and the gloves,
are also soaked in transfer buffer. The “sandwich” is set up so that the positively charge
side is underneath the membrane holding the protein gel on top.

The use of filters

prevents leakage of proteins outside of the membrane. The filter pad is placed first,
followed by the PVDF membrane, the protein gel, and another filter pad on top.

For

every layer of material added onto the system, a cylindrical tube is used to flatten out
the transfer units so as to avoid the formation of air bubbles. Once the system is
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constructed, a 25 V current is produced overnight for the proteins to transfer onto the
pvdf membrane at 4oC. The transfer apparatus is disassembled, and the pvdf
membrane is taken to wash in a dish with multiple washes of H2O.
Protein Visualization – Ponceau S stain from Sigma is used to stain the membrane and
visualize the transfer of proteins in the following way. The membrane is immersed in
sufficient Ponceau S Staining Solution and stained for 5 minutes. The membrane is
then rinsed with distilled water until the background is clear.
Clearing of the Ponceau Stain – After proteins are visualized, the membrane is rinsed in
an aqueous solution of 0.1M NaOH.

The membrane is then rinsed with running

distilled water for 2-3 minutes, and is ready to be used for immunological detection. A
pencil is used to mark over the bands from the marker lane to ensure the proper
location of the molecular sizes. The excess of membrane is trimmed away and rinsed
for 5 minutes in PBSt buffer.
Antibody Incubation – The membrane blot is incubated in 1:500 of the P. Tech primary
Antibody overnight in the cold room on a shaker. The final volume (greater than or
equal to 2 ml) is prepared so that it would sufficiently immerse the membrane in solution
and prevent drying out the membrane. The chamber of incubation is covered with an
aluminum foil to prevent evaporation.

The following day, the blot is rinsed with 3

changes of TBS-tr (2X 5 min, 1X 15 min) on a shaker.

The membrane is then

incubated with anti-rabbit 2nd Ab conjugated with HRP with the optimized dilution of
1:2000 in blocking buffer. This is incubated for 1 hour at room temperature on a shaker
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with sufficient volume to cover the membrane and prevent it from drying out.

The blot

is then rinsed with 3 change of PBSt (2X2 min, 1X15 min) on a shaker at high speed.
Film Developing – The film developing procedure is done inside a dark room following
regular lab protocol with a filtered film box in the dark. Basically, the Super-Signal West
Dura Extended Duration Substrate from Thermo Fisher is first prepared with 1:1 ratio of
the solution A and solution B in the kit just prior to its use. The transfer membrane is
transferred onto a plastic sheet and the prepared ECL mixture is added onto it and
allowed to react for 5 minutes, making sure not to let any part of the membrane dry out.
The membrane is then covered with the same plastic sheet and taped inside of the
developing cassette. An absorbent tissue is used to remove excess liquid and press
out any bubbles from between the blot and the membrane filter.
Membrane Stripping – The membrane is stripped with a mild stripping buffer (pH 2.2)
consisting of 15 g glycine, 1g SDS, 10ml Tween 20. The process followed for stripping
the membrane is by discarding the solution in between each of the following steps: 10
minutes incubation, 10 minutes PBS, 10 minutes PBS, 10 minutes PBS, 5 minutes
TBST (0.1%), and 5 minutes on TBST (0.1%) again.
Protein quantification results – Changes in the protein levels of NINJ2 are quantified
using the ratio of the relative densities of the signals in the western blots. The raw data
from ImageJ along with details of the normalized relative density (NRD) calculation and
t-test results are shown below.
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